뇌 바이오마커 시장 : 제품, 적응증, 최종사용자, 용도별 - 세계 예측(2025-2030년)

The Brain Biomarkers Market was valued at USD 8.94 billion in 2023, expected to reach USD 10.54 billion in 2024, and is projected to grow at a CAGR of 17.90%, to USD 28.33 billion by 2030.

Brain biomarkers are measurable indicators of biological processes within the brain, often used for assessing neurological conditions. They are vital for diagnosing and monitoring diseases like Alzheimer's, Parkinson's, and various psychiatric disorders. These biomarkers range from genetic and proteomic to imaging and physiological signals. The necessity of brain biomarkers lies in their ability to facilitate early diagnosis, track disease progression, and tailor personalized treatment plans, significantly improving patient outcomes and healthcare efficiency.

The application of brain biomarkers spans diagnostics, drug development, and therapeutic monitoring. They are employed in hospitals, research institutes, and clinical labs, serving neurologists, psychiatrists, and other healthcare professionals. The market for brain biomarkers is bolstered by increasing prevalence of neurological disorders, growing demand for personalized medicine, and advances in biomarker technologies. Emerging opportunities include the integration of AI and machine learning to enhance biomarker discovery and analysis, as well as the exploration of biomarkers in the mental health domain.

Key growth factors include technological advancements in neuroimaging and genomics, rising awareness about brain health, and increasing investments in precision medicine. However, challenges such as the high cost of biomarker discovery and validation, regulatory complexities, and limited availability of longitudinal data pose significant hurdles. Moreover, ethical considerations related to genetic testing and data privacy could impact market dynamics.

Innovative areas ripe for exploration include multi-omics approaches to detect composite biomarkers, development of non-invasive biomarker detection methods, and collaborations between biotech firms and research institutions for accelerated R&D. A deeper focus on personalized health approaches, integrating patient-specific data to refine predictive models, holds promise for market expansion.

In conclusion, the brain biomarker market is primed for growth, driven by technological advancements and healthcare demand. Addressing challenges requires strategic investments in research, cross-disciplinary collaborations, and robust regulatory frameworks to navigate ethical and technical landscapes while capitalizing on emerging opportunities for market innovation and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Biomarkers Market

The Brain Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Improved knowledge of neurologic diseases and R&D investment to treat growing geriatric population with brain disorder
  • Need for invasive brain tastings, effective drug development, faster diagnosis, and new treatment option
  • Detection and interpretation to support clinical decisions and patient interventions
• Market Restraints
  • Lack of consumer awareness
• Market Opportunities
  • Evolving biomarker data management platforms to support biomarker-guided drug development and translational research
  • Incorporation of detectable parameters with brain biomarkers to improve clinical decision making
• Market Challenges
  • Complexity of neuroinflammation exacerbated by substantial biological heterogeneity

Porter's Five Forces: A Strategic Tool for Navigating the Brain Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Biomarkers Market

A detailed market share analysis in the Brain Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Biomarkers Market

A strategic analysis of the Brain Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Advanced Brain Monitoring, Inc, Biognosys AG, BrainScope Company, Inc., F. Hoffmann-La Roche AG, GE Healthcare, Johnson & Johnson, Lifesign LLC, Magstim EGI, Merck KGaA,, Natus Medical Inc., NeuroVista Corporation, Nexus-DX, PhenoSwitch Bioscience, Seimens Healthnineers, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Biomarker Analyzers and Biomarker Test Kits.
• Based on Indication, market is studied across Alzheimer's Disease, Huntington's Disease, MND & ALS, Parkinson's Disease, and Stroke.
• Based on End-Users, market is studied across Ambulatory Surgical Centers, Diagnostic Laboratories, Hospitals, and Research Laboratories.
• Based on Application, market is studied across Diagnosis and Drug Discovery & Development.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Improved knowledge of neurologic diseases and R&D investment to treat growing geriatric population with brain disorder
    • 5.1.1.2. Need for invasive brain tastings, effective drug development, faster diagnosis, and new treatment option
    • 5.1.1.3. Detection and interpretation to support clinical decisions and patient interventions
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of consumer awareness
  • 5.1.3. Opportunities
    • 5.1.3.1. Evolving biomarker data management platforms to support biomarker-guided drug development and translational research
    • 5.1.3.2. Incorporation of detectable parameters with brain biomarkers to improve clinical decision making
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity of neuroinflammation exacerbated by substantial biological heterogeneity
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Brain Biomarkers Market, by Product

• 6.1. Introduction
• 6.2. Biomarker Analyzers
• 6.3. Biomarker Test Kits

7. Brain Biomarkers Market, by Indication

• 7.1. Introduction
• 7.2. Alzheimer's Disease
• 7.3. Huntington's Disease
• 7.4. MND & ALS
• 7.5. Parkinson's Disease
• 7.6. Stroke

8. Brain Biomarkers Market, by End-Users

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Diagnostic Laboratories
• 8.4. Hospitals
• 8.5. Research Laboratories

9. Brain Biomarkers Market, by Application

• 9.1. Introduction
• 9.2. Diagnosis
• 9.3. Drug Discovery & Development

10. Americas Brain Biomarkers Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Brain Biomarkers Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Brain Biomarkers Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Advanced Brain Monitoring, Inc
• 2. Biognosys AG
• 3. BrainScope Company, Inc.
• 4. F. Hoffmann-La Roche AG
• 5. GE Healthcare
• 6. Johnson & Johnson
• 7. Lifesign LLC
• 8. Magstim EGI
• 9. Merck KGaA,
• 10. Natus Medical Inc.
• 11. NeuroVista Corporation
• 12. Nexus-DX
• 13. PhenoSwitch Bioscience
• 14. Seimens Healthnineers
• 15. Thermo Fisher Scientific Inc.